












Rosemary A. Kozar, M.D., Ph.D.
Trauma Surgeon
Memorial Hermann Hospital
Associate Professor of Surgery
University of Texas
Houston Medical School



Bruce A. McKinley, Ph.D.
Associate Professor of
Surgery
University of Texas
Houston Medical School



Christine S. Cocanour, M.D. Trauma Surgeon Memorial Hermann Hospital Associate Professor of Surgery University of Texas Houston Medical School

## NORTHFIELD LABORATORIES STUDY SPONSOR

Developer of the blood substitute *PolyHeme*\*

Conducted multiple studies with *PolyHeme*\*

Most studies have been in severely injured patients

#### PURPOSE OF STUDY

To compare PolyHeme® to standard of care

#### PURPOSE OF STUDY

To compare *PolyHeme*® to standard of care treatment of "hemorrhagic shock" in severely

#### **PURPOSE OF STUDY**

To compare *PolyHeme*® to standard of care treatment of "hemorrhagic shock" in severely injured patients starting at the scene of injury

#### WHAT IS HEMORRHAGIC SHOCK?

#### WHAT IS HEMORRHAGIC SHOCK?

Hemorrhagic: massive bleeding


#### WHAT IS HEMORRHAGIC SHOCK?


Hemorrhagic: massive bleeding


Shock: life-threatening condition


Dangerously low blood pressure
Internal organs don't receive enough oxygen
May cause death of severely injured patients


WHAT IS THE STANDARD OF CARE?









































# EXPERIENCE WITH POLYHEME® 5 clinical trials with > 300 treated patients

## EXPERIENCE WITH POLYHEME® 5 clinical trials with > 300 treated patients Extensively studied in hospitalized trauma patients

EXPERIENCE WITH POLYHEME<sup>5</sup>

5 clinical trials with > 300 treated patients

Extensively studied in hospitalized trauma patients

Carries as much oxygen as banked blood

#### EXPERIENCE WITH POLYHEME

5 clinical trials with > 300 treated patients

Extensively studied in hospitalized trauma patients

Carries as much oxygen as banked blood

Reduces the need for banked blood transfusion

#### EXPERIENCE WITH POLYHEME®

5 clinical trials with > 300 treated patients

Extensively studied in hospitalized trauma patients

Carries as much oxygen as banked blood

Reduces the need for banked blood transfusion

Shown to be quite safe

#### EXPERIENCE WITH POLYHEMES

5 clinical trials with > 300 treated patients

Extensively studied in hospitalized trauma patients

Carries as much oxygen as banked blood

Reduces the need for banked blood transfusion

Shown to be quite safe

Has kept patients alive who have lost all of their own blood

#### TRIAL DESIGN AT THE SCENE OF INJURY

Severely injured trauma patients will be assigned to one of two treatments by chance

## TRIAL DESIGN AT THE SCENE OF INJURY

Severely injured trauma patients will be assigned to one of two treatments by chance



Standard of Care

PolyHeme

#### TRIAL DESIGN AT THE SCENE OF INJURY


Severely injured trauma patients will be assigned to one of two treatments by chance





Standard of Care


PolyHeme<sup>-</sup>

Primary Endpoint Mortality at 30 days










## Traditionally required for all research studies that compare two treatments (standard vs. investigational) Patients are informed of the potential risks and potential benefits associated with each of these treatments Patients choose whether to participate in the study



## A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria Patients' lives must be at risk

### A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria

Patients' lives must be at risk

Available treatments are not satisfactory

## A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria

Patients' lives must be at risk

Available treatments are not satisfactory

Patients are unable to give consent

## A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria

Patients' lives must be at risk

Available treatments are not satisfactory

Patients are unable to give consent

Potential risks are reasonable

## A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria

Patients' lives must be at risk

Available treatments are not satisfactory

Patients are unable to give consent

Potential risks are reasonable

Participation in the research may provide a direct benefit to the patient

## A federal regulation (21 CRF 50.24) created in 1996

Research study must meet the specific criteria

Patients' lives must be at risk

Available treatments are not satisfactory

Patients are unable to give consent

Potential risks are reasonable

Participation in the research may provide a direct benefit to the patient

The research could not be practicably carried out without an exemption

The Food and Drug Administration (FDA) is the federal agency that regulates investigational studies

The FDA has agreed to permit the performance of this study by "Waiver of Consent"

The FDA has agreed to permit the performance of this study by "Waiver of Consent"

The Institutional Review Board (IRB) is a group of medical, scientific, and nonscientific members of the local community

The FDA has agreed to permit the performance of this study by "Waiver of Consent"

The IRB reviews and approves all research on humans and has a primary responsibility to assure patient welfare and safety

The FDA has agreed to permit the performance of this study by "Waiver of Consent"

The IRB at UT Houston has approved this research study pending adequate and favorable community consultation


The FDA has agreed to permit the performance of this study by "Waiver of Consent"

The IRB at UT Houston has approved this research study pending adequate and favorable community consultation

This presentation is part of our community consultation

#### CONSENT SAFEGUARDS

If possible, the patient or a legally authorized representative (LAR) will be asked to give consent before the patient is enrolled in the study



#### CONSENT SAFEGUARDS

If possible, the patient or a legally authorized representative (LAR) will be asked to give consent before the patient is enrolled in the study

If consent cannot be obtained before enrollment, frequent attempts will be made to contact the patient's LAR and family to describe the study

#### CONSENT SAFEGUARDS

If possible, the patient or a legally authorized representative (LAR) will be asked to give consent before the patient is enrolled in the study

If consent cannot be obtained before enrollment, frequent attempts will be made to contact the patient's LAR and family to describe the study

The patient, family members, or a legally authorized representative may decide to withdraw the patient at any time

#### Questions?